Edit
Novira Therapeutics
http://www.noviratherapeutics.com/Last activity: 30.04.2021
Probably Closed
Employees: 51-200
Total raised: $48M
Founded date: 2009
Investors 1
| Date | Name | Website |
| 30.04.2021 | Mid-Atlant... | magfund.co... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 25.03.2013 | Series A | $25M | - |
| 24.08.2012 | Series A | $23M | - |
Mentions in press and media 11
| Date | Title | Description |
| 09.11.2015 | Johnson & Johnson Acquires Novira Therapeutics | Novira Therapeutics Inc., a Doylestown, MA-based clinical-stage company developing novel therapeutic candidates for curative treatments of chronic Hepatitis B virus (HBV) infection, has been acquired by Johnson & Johnson (NYSE: JNJ). Th... |
| 24.12.2014 | Maker of Hepatitis B antiviral raises $9M | About one third of the world’s population is infected with Hep B, according to the World Health Organization; about 5 percent have a chronic form of the disease. The infection leads to more than 1 million deaths per year, the WHO says. Prom... |
| 26.03.2013 | Novira Therapeutics Inks $25M Series A | DOYLESTOWN, PA, Novira Therapeutics, Inc. today announced the completion of its Series A financing after securing $7.5 million from new investor Versant Ventures. >> Click here for more funding data on Novira Therapeutics >>... |
| 25.03.2013 | Novira Therapeutics Secures $7.5M; Completes $25M Series A Financing | Novira Therapeutics, Inc., a Radnor, PA-based antiviral drug discovery company, secured $7.5m and completed its $25m Series A financing. New investor Versant Ventures joined 5AM Ventures and Canaan Partners, which led the first closing of t... |
| 25.03.2013 | Biotechnology company adds new investor in its fight against Hepatitis B virus | In an e-mail to clarify the financing, Chief Scientific Officer and President Osvaldo Flores said the financing round followed a two-step closing model in which investors 5AM and Canaan led the first closing in August with a partial syndica... |
| 24.08.2012 | Novira Therapeutics Secures $23M in Series A Financing | Novira Therapeutics Inc., a Radnor, PA-based antiviral drug discovery company, has secured $23m in Series A financing. The round was co-led by new investors 5AM Ventures and Canaan Partners with participation from WuXi PharmaTech as well as... |
| 24.08.2012 | Novira Therapeutics raises $23M for hepatitis B treatment that attacks DNA of virus | Osvaldo (Lalo) Flores, the president and chief scientific officer of Novira Therapeutics in Radnor, Pennsylvania, told MedCity News in a phone interview that the biotechnology company’s capsid-targeting antivirals entering preclinical devel... |
| 27.07.2011 | Novira Therapeutics Completes Second Round of Seed Financing | Novira Therapeutics, Inc., a Radnor, Pennsylvania-based drug discovery company developing therapeutics for the treatment of viral diseases, including HBV and HIV, has completed a second round of seed financing. The round was led by three Ph... |
| - | Novira Therapeutics raises $23M for hepatitis B treatment that attacks DNA of virus | A biotechnology company with a novel drug treatment for hepatitis B and HIV patients could change the way drugs combat viruses. The drug, under development, which targets the outer shell, or capsids, of the viruses, has secured $23 million ... |
| - | Biotechnology company adds new investor in its fight against Hepatitis B virus | A biotechnology company seeking to eradicate the Hepatitis B virus has added a new investor to its backers to close a $25 million Series A round. Novira Therapeutics in Radnor, Pennsylvania added Versant Ventures — a venture firm that backs... |
Show more